151 Migraine attack incidence in relation to ovulation 7 Table 1: Baseline characteristics LHC group WHAT-hormone subgroup Number of patients 554 31 Number of menstrual cycles 2522 58 Number of menstrual cycles per patient 4 [3 – 6] 2 [2 – 2] Cycle length (mean ± SD) 27.3 ± 2.6 27.5 ± 3.4 Follow-up time (days and interquartile range) 80 [51 – 128] 53 [49 – 55] Age (years ± SD) 38.9 ± 8.4 37.7 ± 8.3 BMI (kg/m2) 24.0 ± 4.3 23.3 ± 3.4 Diagnosis Migraine without aura, n (%) Migraine with aura, n (%) 356 (64) 198 (36) 21 (68) 10 (32) Menstrual migraine (MM) diagnosis Yes, n (%) No, n (%) No diagnosis possible*, n (%) 234 (42) 275 (50) 45 (8) 31 (100) Monthly migraine days (MMD ± SD) 5.4 ± 2.8 4.5 ± 2.5 Monthly headache days (MHD ± SD) 8.8 ± 4.6 7.4 ± 3.5 Monthly acute medication days (MAMD ± SD) 5.8 ± 3.8 5.2 ± 2.9 Adherence to e-diary (%) 99 [94 – 100] 100 [95 – 100] *Menstrual migraine was defined as women suffering from a perimenstrual migraine attack in two out of three menstrual cycles, and thus could not be determined in women who were followed during only 2 menstrual cycles. SD = standard deviation. Figure 2 and 3 depict the probability of a migraine attack on each standardized day of the menstrual cycle for the total cohort and the WHAT-hormone subgroup. Visual interpretation shows migraine occurrence was highest during perimenstrual window and lowest during the ovulatory window and luteal phase.
RkJQdWJsaXNoZXIy MjY0ODMw